Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.

GLG News by Oncologists (US)

Donald Fleming, Division Head of Hematology and Oncology

Donald FlemingDivision Head of Hematology and OncologyDAVIS HEALTH SYSTEM INC What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Omapro will fill a CML void

November 14, 2009

US FDA accepts ChemGenex's Omapro NDA filing to treat CML, grants priority review status | www.pharmabiz.com

Patients with CML have a good prognosis when treated with TKI's An exception is the ones that develope a particular mutation known as T315IOnly SCT seems to be effective in this group of patients and maybe too morbid of therapy for many patients

Eric Whitman, Medical Director, Office of Grants and Research

Eric WhitmanMedical Director, Office of Grants and ResearchATLANTIC HEALTH SYSTEM INC What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Synta Drug for Metastatic Melanoma Not Dead Yet (?)

November 3, 2009

Synta Pharmaceuticals Announces Updated Elesclomol SYMMETRYSM Data Presented at Melanoma XIII | www.businesswire.com

Updated data presented at an annual Melanoma conference suggests the drug Elesclomol may benefit a subset of patients treated on a Phase III trial. This Synta Pharmaceuticals-sponsored trial in metastatic melanoma patients was stopped for safety (survival) concerns in February 2009, but the updated analysis suggests that a commonly available biomarker may identify patients who appear to benefit from Elesclomol treatment.This news is important because it may allow Synta to continue to pursue approval for Elesclomol in either melanoma patients or in other cancers. They will report an updated survival analysis twelve months after the protocol was stopped, after February 2010. Further info from Synta is expected soon.

Eric Whitman, Medical Director, Office of Grants and Research

Eric WhitmanMedical Director, Office of Grants and ResearchATLANTIC HEALTH SYSTEM INC What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Delcath Phase III trial for metastatic melanoma completes enrollment

November 3, 2009

Delcath Systems, Inc. Completes Phase III Study Enrollment | www.reuters.com

The Delcath Systems Percutaneous Hepatic Perfusion (PHP) trial to treat patients with metastatic melanoma has completed enrollment and now must track patients, record data, and analyze results.This trial was apparently enrolled on schedule and the company is targeting 2010 for FDA regulatory submission.

Eric Whitman, Medical Director, Office of Grants and Research

Eric WhitmanMedical Director, Office of Grants and ResearchATLANTIC HEALTH SYSTEM INC What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Plexxikon Drug for Melanoma Continues to Show Great Promise

October 14, 2009

Researchers herald 'breakthrough' skin cancer therapy | www.fiercebiotech.com

The new drug PLX-4032, being developed by Plexxikon and Roche, continues to show impressive short term results in melanoma patients with specific BRAF mutations, with a reported 70% tumor response rate.

Donald Fleming, Division Head of Hematology and Oncology

Donald FlemingDivision Head of Hematology and OncologyDAVIS HEALTH SYSTEM INC What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Triple negative Breast Cancer Strategies

October 14, 2009

MediGene completes patient recruitment into EndoTAGTM-1 phase II breast cancer trial | www.pharmabiz.com

Triple negative Breast cancer has been a phenotype with little hope up until recentlyWhile advances in hormonal therapy and Her2 blocking agents has revolutionized ER/PR + and Her 2 positive breast cancer therapy, triple negative breast cancer pulls down the outcomes, with similar responses as for non small cell lung cancer

Donald Fleming, Division Head of Hematology and Oncology

Donald FlemingDivision Head of Hematology and OncologyDAVIS HEALTH SYSTEM INC What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Farletuzumab (F) helps the ovarian cancer patients that do well, do well?

September 25, 2009

Farletuzumab Data Presented on Phase II Clinical Trial in First-Relapsed Ovarian Cancer Subjects | www.pipelinereview.com

F recently demonstrated a great majority of platinum sensitive patients respond when given in combination with a platinum based regimen in recurrent ovarian caPlatinum sensitive patients typically do well with platinum based intervention, but it's the platinum resistant ( denovo or delayed) that we have a problem with

Donald Fleming, Division Head of Hematology and Oncology

Donald FlemingDivision Head of Hematology and OncologyDAVIS HEALTH SYSTEM INC What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Herceptin for Her2 + gastric cancer, If you can find one

September 25, 2009

Roche's Herceptin provides impressive survival benefit in HER2-positive advanced gastric cancer | www.pharmabiz.com

Herceptin recently reported in Phase II ASCo data to enhance chemo in Her 2 positive gastric cancer

Donald Fleming, Division Head of Hematology and Oncology

Donald FlemingDivision Head of Hematology and OncologyDAVIS HEALTH SYSTEM INC What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

REGORAFENIB joins a crowd of TKI's for RCC

September 25, 2009

Bayer's anti-cancer drug regorafenib shows stabilization or regression in 81% of kidney cancer patients | www.pharmabiz.com

RCC now has multiple TKI"S either approved or in development for txThe disease control rate seems to be a popular and effective endpoint to get drugs for RCC approved

Eric Whitman, Medical Director, Office of Grants and Research

Eric WhitmanMedical Director, Office of Grants and ResearchATLANTIC HEALTH SYSTEM INC What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Gleevec shows promise as targeted melanoma treatment

July 27, 2009

A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT | meeting.ascopubs.org

Gleevec (Imatinib), a target specific cancer treatment drug against KIT oncogene mutations, shows early evidence of efficacy in treating melanomas with susceptible genetic mutations, further support for a personalized medicine, targeted therapy, approach to treating melanoma and cancers in general.

Eric Whitman, Medical Director, Office of Grants and Research

Eric WhitmanMedical Director, Office of Grants and ResearchATLANTIC HEALTH SYSTEM INC What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

PLX-4032, the new great hope for targeted therapy in melanoma

July 27, 2009

Plexxikon announces PLX4032 Phase I Data showing objective responses in metastatic melanoma patients | www.plexxikon.com

PLX-4032, a Plexxikon drug being co-developed with Roche, has shown remarkable results in a Phase I trial for melanoma and appears poised for rapid progression through Phase II and Phase III testing with perhaps accelerated FDA approval on the horizon.

Page : 12345678910Next1 to 10 of 255

Leading institutions connect with members of the Healthcare councils through GLG

Most Popular Healthcare News